Message Font: Serif | Sans-Serif
No. of Recommendations: 3
I've owned it for a couple of years.

Bought as a dividend play only. PDLI has fixed this dividend on the low side so they can attack debt. IMO they are pretty shareholder-friendly.

They have a lot of cash with which they propose to purchase new royalty streams; heretofore this hasn't happened.

Most of the patents expire in 2014 and 2015. So the business will start into run-off (without new revenue streams)relatively soon. They have about 6-7 employees.

Current picture:

Two large wild cards:

1. Bapineuzumab. If this actually works for Alzheimers then a potential revenue stream opens up. I don't know when this patent expires (or, at least, the revenue part of it for PDLI). There's also another mab in development for a-beta.

2. There is also litigation with Roche which may result in a windfall for PDLI. (Or, not)

I am kind of on the fence here. Mgmt hasn't shown a way forward--and, indeed, may not know what to do until some chips fall.

They have 2x debt as cash but have shown consistent interest in paying off debt and reducing interest charges.

There are probably dividend yields out there w/o so much uncertainty (I own plenty with uncertainty) but it is worth watching as now and then it dips into the mid $5's (where I own it) and gets awfully enticing...

Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.